Evidence map›Paper›PMID 40141849›Full record

ArticleLife (Basel, Switzerland)2025

Therapeutic Challenges and Emerging Strategies for

Sıdıka Gülkan Özkan, Ali Kimiaei, Seyedehtina Safaei, Mutlu Karkucak, Mustafa Nuri Yenerel, Aslı Yüksel Öztürkmen, Burak Alp, Hasan Atilla Özkan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sıdıka Gülkan ÖzkanDepartment of Internal Medicine, Division of Hematology, Faculty of Medicine, Bahçeşehir University, 34734 Istanbul, Turkey.ORCID 0000-0001-5917-8071
Ali KimiaeiDepartment of Internal Medicine, Division of Hematology, Faculty of Medicine, Bahçeşehir University, 34734 Istanbul, Turkey.
Seyedehtina SafaeiDepartment of Internal Medicine, Division of Hematology, Faculty of Medicine, Bahçeşehir University, 34734 Istanbul, Turkey.
Mutlu KarkucakGenetic Diseases Assessment Center, İstinye University, 34010 Istanbul, Turkey.
Mustafa Nuri YenerelDepartment of Internal Medicine, Division of Hematology, Istanbul Medical Faculty, Istanbul University, 34093 Istanbul, Turkey.
Aslı Yüksel ÖztürkmenDepartment of Internal Medicine, Division of Hematology, Sivas Numune Hospital, 58060 Sivas, Turkey.
Burak AlpAdult Hematology and Bone Marrow Transplantation Unit, Medical Park Göztepe Hospital, 34732 Istanbul, Turkey.
Hasan Atilla ÖzkanDepartment of Internal Medicine, Division of Hematology, Faculty of Medicine, Bahçeşehir University, 34734 Istanbul, Turkey.ORCID 0000-0001-5590-972X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative neoplasm (MPN) with eosinophilia associated with

Indexed as

eosinophilic disorderFIP1L1-PDGFRA T674I mutationimatinib resistancemyeloproliferative neoplasmPTPN11 mutation

Identifiers

PMID40141849
PMCPMC11944135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.